Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Endocrine therapy is the treatment of choice in hormone receptor-positive breast cancer. However, the effectiveness of anti-hormone drugs, such as tamoxifen, is limited because of the development of resistance, ultimately leading to disease progression and patient mortality. Using in vitro cell models of anti-hormone resistance, we have previously demonstrated that altered growth factor signalling contributes to an endocrine insensitive phenotype. Significantly, our recent studies have revealed that the acquisition of endocrine resistance in breast cancer is accompanied by a greatly enhanced migratory and invasive phenotype. Furthermore, therapeutic intervention using anti-growth factor monotherapies, despite an initial growth suppressive phase, again results in the development of a resistant state and a further augmentation of their invasive phenotype. Using the dual specific Src/Abl kinase inhibitor, AZD0530, we have highlighted a central role for Src kinase in promoting the invasive phenotype that accompanies both anti-hormone and anti-growth factor resistance. Importantly, the use of Src inhibitors in combination with anti-growth factor therapies appears to be additive, producing a marked inhibitory effect on cell growth, migration and invasion and ultimately prevents the emergence of a resistant phenotype. These observations suggest that the inhibition of Src activity may present a novel therapeutic intervention strategy, particularly when used as an adjuvant in endocrine-resistant breast disease, with the potential to delay or prevent the acquisition of subsequent resistance to anti-growth factor therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251
Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., & Yeatman, T. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201496 · Cited by 200
Cited by
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
“Interestingly, SRC plays a central role in the cross talk between estrogen and androgen receptors (40, 41), and SRC expression and activity have been linked to resistance to anti-hormonal therapy (42, 43).”
Structure and Characterization of a Covalent Inhibitor of Src Kinase
Gurbani, D., Du, G., Henning, N. J., Rao, S., Bera, A. K., Zhang, T., Gray, N. S., & Westover, K. D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00081 · Cited by 29
“Src has been implicated in mechanisms that underlie the development of hormone therapy resistance in breast cancer (McDonnell and Norris, 2002; Hiscox et al., 2006) and resistance to chemotherapy in triple-negative breast cancer (Wu et al., 2016).”
Background
Metadata
- Authors
- Hiscox, S., Morgan, L., Green, T., & Nicholson, R. I.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2006-12
- Volume
- 13
- Issue
- Supplement_1
- Pages
- S53-S59
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2121123486
- Cited by
- 57
- References
- 2
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. https://app.cochat.ai/papers/10.1677/erc.1.01297
- The paper
- Hiscox, S., Morgan, L., Green, T., & Nicholson, R. I. (2006). Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer. https://doi.org/10.1677/erc.1.01297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.